^
Association details:
| Biomarker: | FGFR1 amplification + RAF1 amplification + CDK6 amplification |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC
Excerpt:
...liquid biopsy revealed additional increase of tumor molecular burden (somatic alteration burden, 16.4% v 12.2%), with persistence of FGFR1 amplification and reappearance of RAF-1 amplification, as well as the emergence of CDK6 amplification...An FDG-PET scan and a CT scan documented progression of disease...Compassionate use of the FGFR inhibitor ponatinib was requested, because of the unavailability of a selective FGFR inhibitor…Unfortunately, treatment was poorly tolerated...Ponatinib was discontinued after 12 weeks because of further disease progression with adrenal metastasis...
DOI:
10.1200/PO.19.00243
Test:
